Oppenheimer Holdings Stock News

Equities researchers at Oppenheimer started coverage on shares of Caribou Biosciences (NASDAQ:CRBU) in a research report issued on Tuesday, The Fly reports. The brokerage set an outperform rating on the stock. CRBU has been the topic of a number of other reports. SVB Leerink initiated coverage on Caribou Biosciences in a research note on Tuesday, []

TheStreet lowered shares of Conformis (NASDAQ:CFMS) from a c rating to a d+ rating in a report published on Friday, TheStreetRatingsTable reports. Several other analysts have also commented on the stock. Zacks Investment Research raised shares of Conformis from a sell rating to a hold rating in a research report on Tuesday, November 16th. Oppenheimer []

Investment analysts at Wedbush assumed coverage on shares of Consensus Cloud Solutions (NASDAQ:CCSI) in a research report issued on Tuesday, The Fly reports. The firm set an outperform rating on the stock. Separately, Oppenheimer assumed coverage on shares of Consensus Cloud Solutions in a research report on Thursday, November 4th. They issued an outperform rating []

CHICAGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. ("Chicago Atlantic"), a commercial real estate finance company that intends to elect and qualify to be taxed as a REIT under Section 856 of the Internal Revenue Code of 1986, today announced the filing of a registration statement on Form S-11 related to an initial public offering of 6,250,000 shares of its common stock. The price range for this offering is currently $16.00 to $18.00 per share of common stock. Chicago Atlantic has applied to have its common stock approved for listing on the NASDAQ Global Market under the symbol "REFI." In connection with this offering, Chicago Atlantic is expected to grant the underwriters a 30-day option to purchase up to an additional 937,500 shares of its common stock. The completion of the proposed offering depends upon several factors, including market and other conditions. Chicago Atlantic is managed by Chicago Atlantic REIT Manager, LLC. Chicago Atlantic''s primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time primarily through consistent current income dividends and other distributions and secondarily through capital appreciation.

Deere & Company (NYSE:DE) Equities researchers at Oppenheimer issued their Q1 2022 earnings estimates for Deere & Company in a report released on Friday, November 26th. Oppenheimer analyst K. Owen expects that the industrial products company will earn $3.48 per share for the quarter. Oppenheimer also issued estimates for Deere & Companys Q2 2022 [] The post Deere & Company (NYSE:DE) Forecasted to Post Q1 2022 Earnings of $3.48 Per Share appeared first on ETF Daily News .

Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) Oppenheimer lowered their FY2021 EPS estimates for shares of Clarus Therapeutics in a note issued to investors on Wednesday, November 24th. Oppenheimer analyst L. Gershell now forecasts that the company will post earnings per share of ($8.29) for the year, down from their previous forecast of ($6.82). Oppenheimer has []

Oppenheimer (NYSE: OPY) is one of 53 public companies in the Security brokers & dealers industry, but how does it compare to its rivals? We will compare Oppenheimer to similar businesses based on the strength of its analyst recommendations, risk, dividends, institutional ownership, profitability, valuation and earnings. Insider and Institutional Ownership 44.3% of Oppenheimer shares []

Oppenheimer (NYSE: OPY) is one of 53 public companies in the Security brokers & dealers industry, but how does it weigh in compared to its competitors? We will compare Oppenheimer to related companies based on the strength of its earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This is a breakdown []

Oppenheimer (NYSE: OPY) is one of 53 publicly-traded companies in the Security brokers & dealers industry, but how does it contrast to its peers? We will compare Oppenheimer to similar businesses based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, risk and valuation. Profitability This table compares Oppenheimer and its peers []

Synlogic Inc (NASDAQ:SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, stock fell 1.52% (As on Nov 26, 10:46:42 AM UTC-4,… The post Synlogic Inc (NASDAQ:SYBX) Upgraded by Oppenheimer to Outperform appeared first on FXDailyReport.Com .

Medtronic (NYSE:MDT) had its target price reduced by analysts at Oppenheimer from $150.00 to $145.00 in a report issued on Wednesday, The Fly reports. The brokerage presently has an outperform rating on the medical technology companys stock. Oppenheimers target price points to a potential upside of 26.70% from the companys current price. Oppenheimer also issued []

Marvell Technology (NASDAQ:MRVL) had its target price raised by Oppenheimer from $75.00 to $100.00 in a report released on Tuesday, Analyst Price Targets reports. They currently have an outperform rating on the semiconductor companys stock. A number of other equities analysts also recently commented on MRVL. Jefferies Financial Group lifted their target price on Marvell []

Oppenheimer (NYSE: OPY) is one of 53 publicly-traded companies in the Security brokers & dealers industry, but how does it weigh in compared to its rivals? We will compare Oppenheimer to related companies based on the strength of its analyst recommendations, institutional ownership, risk, dividends, earnings, valuation and profitability. Dividends Oppenheimer pays an annual dividend []

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lifted by Oppenheimer from $84.00 to $95.00 in a research report report published on Monday, The Fly reports. The firm currently has a market perform rating on the biotechnology companys stock. Oppenheimer also issued estimates for BioMarin Pharmaceuticals Q4 2021 earnings at ($0.10) EPS, Q1 2022 earnings at []

XPO Logistics, Inc. (NYSE:XPO) Equities researchers at Oppenheimer issued their Q4 2022 earnings per share (EPS) estimates for shares of XPO Logistics in a research report issued to clients and investors on Sunday, November 21st. Oppenheimer analyst S. Schneeberger forecasts that the transportation company will post earnings per share of $0.97 for the quarter. []